the efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis c patients with cirrhosis, genotypes 1 and 3

Background: the combination of sofosbuvir and daclatasvir can be used to treat all genotypes of hepatitis c. current guidelines for treating hepatitis c cirrhosis do not clarify weather 12 weeks or 24 weeks of treatment is appropriate. objectives: in the present study, we aimed at evaluating the efficacy of sofosbuvir, daclatasvir, and ribavirin given for 12 weeks in treating cirrhotic patients with hepatitis c genotypes 1 and 3 infections. methods: one hundred patients with hepatitis c and cirrhosis infected with genotypes 1 and 3 were included in the present study. they were treated with 1 tablet of a combination pill of 400mg sofosbuvir and 60mgdaclatasvir daily and weight-based ribavirin for 12 weeks. response to treatment was assessed 12 weeks after the end of the treatment with a sensitive assay (svr12). this study was registered with clinicaltrials.gov, id: nct02596880. results: one patient developed increased creatinine level following severe diarrhea and gastroenteritis and was excluded, 1 patient died due to unrelated reasons and 4 others were lost to follow-up. among the 94 patients who finished the study, 92 achieved svr12 (98%, per-protocol, 92% intention-to-treat). none of the patients reported any side effects. of the 100 original patients, 56 were genotype 1 and 44 were genotype 3. one of the two patients not achieving svr12 was genotype 1, and the other two were genotype 3. conclusions: the fixed-dose combination drug of sofosbuvir and daclatasvir given together with weight-base ribavirin for 12 weeks is extremely effective and safe in treating hcv patients with genotypes 1 and 3 and cirrhosis.